knowledge -WSS

knowledge

author：comprehensive 2025-09-14 21:42:39 - browse：282

Adobe

A month after announcing it was seeking strategic alternatives, Akili Interactive, maker of a video game designed to treat ADHD, said it will go private in a merger with Virtual Therapeutics. The deal is expected to net Akili’s shareholders $34 million.

Akili made headlines in 2020 when it received Food and Drug Administration clearance for EndeavorRx, a video game designed to treat pediatric ADHD. Akili went public in 2022 in a deal that valued the company at about $1 billion. But despite several strategic pivots, including shifting to direct-to-consumer sales, the company failed to build a sustainable business model. Akili in April announced it would wind down its existing commercial operations and focus on a licensing deal with Japanese pharma company Shionogi while it figured out the best path forward.

Akili is just one of many health tech companies that are struggling following an explosion of investor interest in digital health during the Covid-19 pandemic. In the last month alone, Better Therapeutics, another company making digital treatments, sold its assets for an undisclosed amount after failing to build a business around its app for type 2 diabetes, and Cue Health, a diagnostics startup, shut down after funding interest in its Covid-19 tests evaporated.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Do masks work? RCTs can't tell us

WSS

Cloning humans is technically possible. It's curious no one has tried

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Pope Francis asks Church to identify 21st

New guidelines on severe brain injury complicate already difficult decisions

Man pleads guilty to raping Ohio girl who ended up traveling across state lines for abortion

The strategy behind pharma's lawsuits over drug pricing reform

entertainment

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Israel withdraws forces after 2

United colonoscopy coverage change 'may cost lives,' doctors say

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

Continuity nursing helped my family in our darkest PICU moments

Why we need to separate burnout from moral injury in health care

Wildfire smoke exposes gaps in outdoor worker protections

New guidelines on severe brain injury complicate already difficult decisions

Novavax promises a turnaround & Lilly roils the obesity market

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

hotspot

EU moves toward latest gene techniques in food production to counter climate change, shortages

Ask STAT: What do you want to know about ChatGPT in medicine?

New guidelines on severe brain injury complicate already difficult decisions

Following judge's order, DOJ releases slightly less

Ask STAT: What do you want to know about ChatGPT in medicine?

With FDA staff opposed to Sarepta therapy, top official intervened

leisure time

hotspot

focus

knowledge